Tharimmune, Inc. THAR 深沪

等待开盘 05-12 09:30:00 美东时间

0.000

0.00%

华盛通

个股概要

Tharimmune Files For $2B Mixed Shelf Offering

-SEC Filing

01-10 05:37
Gold Edges Higher; ISM Manufacturing PMI Falls In October

U.S. stocks traded mixed toward the end of trading, with the Dow Jones index fa...

2025-11-04 03:23
Tharimmune Partners with Intract Pharma to Develop Oral Version of Infliximab for Autoimmune Diseases

Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in inflammation and immunology, announced today that it has entered

2024-09-16 19:08

公司名称	--
行业分类	--
业务描述	Tharimmune, Inc. is a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for inflammation and immunology. It also develops TH104, which is known to suppress chronic, debilitating pruritus or "uncontrollable itching" in PBC, a rare and orphan liver disease with no known cure. The company was founded on March 28, 2017 and is headquartered in Bridgewater, NJ.

派息除权日	每股总股息	派息日期